The designation AOD stands for anti-obesity drug, a development-program name rather than a description of established activity, and the compound remains investigational
Buy larger vials when appropriate Cost per milligram typically decreases with larger vial sizes
doi: 10.3389/fphar.2025.1602976 Received 30 March 2025 Revised 13 November 2025 Accepted 14 November 2025 Published 19 December 2025 Volume 16 - 2025 Edited by Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa Reviewed by Kacper Nijakowski, Poznan University of Medical Sciences, Poland Miriam Njoki Karinja, Science for Africa Foundation, Kenya Updates Copyright 2025 Mazur, Ndokaj, Salerno, Vallone, Ardan, Bietolini, Carrouel, Wilk, Sarig, Ottolenghi and Bourgeois
They are not FDA-approved for weight loss
This distinction helps explain why it progressed into formal obesity trials, whereas the raw fragment itself did not
Brand name versions (Wegovy for semaglutide, Zepbound for tirzepatide) both list at approximately $1,000-1,300 per month without insurance